Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Assessing laryngeal function and hypersensitivity

    Research output: Contribution to journalReviewResearchpeer-review

  1. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Low-frequency variation in TP53 has large effects on head circumference and intracranial volume

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Airway obstruction and bronchial reactivity from age 1 month until 13 years in children with asthma: A prospective birth cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Genetic, Clinical, and Environmental Factors Associated With Persistent Atopic Dermatitis in Childhood

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Mirco Govoni
  • Annalisa Piccinno
  • Germano Lucci
  • Gianluigi Poli
  • Daniela Acerbi
  • Roberta Baronio
  • Dave Singh
  • Piotr Kuna
  • Bo L K Chawes
  • Hans Bisgaard
View graph of relations

BACKGROUND: Asthma guidelines recommend prescription of inhaled corticosteroids at a reduced dosage in children compared to older patients in order to minimize the systemic exposure and risk of unwanted side effects. In children, pressurized metered dose inhalers (pMDI) are recommended in combination with a valved holding chamber (VHC) to overcome the problem of coordinating inhalation with actuation. However, the influence of age and body size on the systemic exposure of drugs to be administered via a pMDI with VHC is still not fully elucidated. Therefore, we aimed to compare the systemic exposure to the active ingredients of a fixed combination of beclometasone-dipropionate/formoterol-fumarate administered via pMDI with VHC in children, adolescents and adults.

METHODS: The pharmacokinetics of formoterol and beclometasone-17-monopropionate (active metabolite of beclometasone-dipropionate) was evaluated over 8 h from three studies, each performed in a different age and body size group. Children (7-11 years, n = 20), adolescents (12-17 years, n = 29) and adults (≥18 years, n = 24) received a single dose of beclometasone/formoterol (children: 200 μg/24 μg, adolescents and adults: 400 μg/24 μg) via pMDI with AeroChamber Plus™.

RESULTS: The systemic exposure in children in comparison to adolescents was equivalent for formoterol while it was halved for beclometasone-17-monopropionate in accordance with the halved dose of beclometasone administered in children (90% CIs within 0.8-1.25 for formoterol and 0.4-0.625 for beclometasone-17-monopropionate). The systemic exposure to beclometasone-17-monopropionate and formoterol was equivalent between adolescents and adults.

CONCLUSIONS: The systemic exposure to the active ingredients of a fixed dose combination of beclometasone/formoterol administered via pMDI with AeroChamber Plus™ correlates with the nominal dose independently of patient age and body size. Thus, dose reduction in relation to age when using a pMDI with VHC may be unnecessary for reducing the systemic exposure in children.

Original languageEnglish
JournalPulmonary Pharmacology and Therapeutics
Volume30
Pages (from-to)102-109
Number of pages8
ISSN1094-5539
DOIs
Publication statusPublished - 16 Apr 2014

ID: 45051061